The Current and Future State of Immune Checkpoint Inhibitors in NSCLC | Supplements And Featured Publications

Dr. Brahmer on the 5-Year Data for Nivolumab/Ipilimumab in NSCLC

July 14, 2022

Julie R. Brahmer, MD, MSc, discusses the significance of the long-term survival data of nivolumab plus ipilimumab seen in the phase 3 CheckMate-227 trial in patients with metastatic non–small cell lung cancer.

Nivolumab/Ipilimumab Demonstrated Long-term Efficacy in Metastatic NSCLC

June 06, 2022

Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.